Repligen Corporation (RGEN) Shares Bought by Conestoga Capital Advisors LLC

Conestoga Capital Advisors LLC raised its position in shares of Repligen Corporation (NASDAQ:RGEN) by 12.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,453,232 shares of the biotechnology company’s stock after purchasing an additional 161,427 shares during the period. Repligen Corporation makes up approximately 2.5% of Conestoga Capital Advisors LLC’s investment portfolio, making the stock its 15th biggest position. Conestoga Capital Advisors LLC owned 3.89% of Repligen Corporation worth $55,688,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. US Bancorp DE raised its position in Repligen Corporation by 1.2% during the second quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock valued at $191,000 after purchasing an additional 54 shares in the last quarter. Pinebridge Investments L.P. raised its position in Repligen Corporation by 1.7% during the second quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock valued at $186,000 after purchasing an additional 76 shares in the last quarter. Arizona State Retirement System raised its position in Repligen Corporation by 0.6% during the second quarter. Arizona State Retirement System now owns 17,726 shares of the biotechnology company’s stock valued at $735,000 after purchasing an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in Repligen Corporation by 0.4% during the second quarter. The Manufacturers Life Insurance Company now owns 26,402 shares of the biotechnology company’s stock valued at $1,095,000 after purchasing an additional 106 shares in the last quarter. Finally, Profund Advisors LLC raised its position in Repligen Corporation by 4.7% during the second quarter. Profund Advisors LLC now owns 6,365 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 286 shares in the last quarter. Institutional investors and hedge funds own 97.91% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.com-unik.info/2017/11/01/repligen-corporation-rgen-shares-bought-by-conestoga-capital-advisors-llc.html.

Shares of Repligen Corporation (RGEN) traded up 1.32% on Wednesday, hitting $37.69. 118,292 shares of the stock traded hands. The firm has a market cap of $1.41 billion, a P/E ratio of 73.76 and a beta of 1.18. The stock has a 50-day moving average price of $39.43 and a 200 day moving average price of $39.96. Repligen Corporation has a 52 week low of $26.16 and a 52 week high of $46.81.

Repligen Corporation (NASDAQ:RGEN) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.15 by $0.05. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. The company had revenue of $32.40 million during the quarter, compared to the consensus estimate of $31.72 million. During the same period in the previous year, the firm posted $0.16 EPS. The firm’s revenue was up 11.0% compared to the same quarter last year. Equities research analysts predict that Repligen Corporation will post $0.59 EPS for the current fiscal year.

Several research analysts have commented on the stock. BidaskClub upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a report on Saturday, August 12th. TheStreet upgraded shares of Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Stephens reiterated an “overweight” rating and set a $50.00 price target on shares of Repligen Corporation in a report on Tuesday, September 26th. Finally, First Analysis upgraded shares of Repligen Corporation from an “equal weight” rating to an “overweight” rating and set a $47.00 price target for the company in a report on Monday, October 2nd. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $45.40.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.

Institutional Ownership by Quarter for Repligen Corporation (NASDAQ:RGEN)

What are top analysts saying about Repligen Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Repligen Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit